Literature DB >> 26363543

Sequence Variants of Uncertain Significance: What to Do When Genetic Test Results Are Not Definitive.

Marc S Greenblatt1.   

Abstract

Clinical genetic testing for cancer predisposition syndromes often identifies DNA changes whose effects cannot be interpreted easily. These changes, often referred to as variants of uncertain significance (VUS), are not useful for clinical management. In contrast with clearly pathogenic mutations, VUS do not firmly diagnose a specific syndrome at the molecular level and cannot be used to identify with certainty which relatives are mutation carriers and which relatives are free of the syndrome. This article discusses the approach to evaluating VUS and how clinicians can play a key role in advancing the field to benefit all patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Gene panels; Genetic testing; Hereditary cancer syndrome; Pathogenic variant; Variants of uncertain significance (VUS)

Mesh:

Year:  2015        PMID: 26363543     DOI: 10.1016/j.soc.2015.06.009

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  6 in total

1.  Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program.

Authors:  David J Hermel; Wendy C McKinnon; Marie E Wood; Marc S Greenblatt
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

2.  Physician interpretation of variants of uncertain significance.

Authors:  Sarah K Macklin; Jessica L Jackson; Paldeep S Atwal; Stephanie L Hines
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

Review 3.  The role of screening MRI in the era of next generation sequencing and moderate-risk genetic mutations.

Authors:  Sarah Macklin; Jennifer Gass; Ghada Mitri; Paldeep S Atwal; Stephanie Hines
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

4.  Influence of Genetic Information on Neonatologists' Decisions: A Psychological Experiment.

Authors:  Katharine Press Callahan; John Flibotte; Cara Skraban; Katherine Taylor Wild; Steven Joffe; David Munson; Chris Feudtner
Journal:  Pediatrics       Date:  2022-03-01       Impact factor: 7.124

5.  Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.

Authors:  Nicole Bryant; Nicole Malpeli; Julia Ziaee; Cornelis Blauwendraat; Zhiyong Liu; Andrew B West
Journal:  Hum Mol Genet       Date:  2021-04-30       Impact factor: 6.150

6.  Current Testing Guidelines: A Retrospective Analysis of a Community-Based Hereditary Cancer Program.

Authors:  Margaret Ward; Betty Elder; Maryon Habtemariam
Journal:  J Adv Pract Oncol       Date:  2021-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.